This HTML5 document contains 53 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n19http://linked.opendata.cz/resource/domain/vavai/subjekt/
n8http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n18http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n16http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F13%3A%230002082%21RIV14-MZ0-65269705/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n11http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F65269705%3A_____%2F13%3A%230002082%21RIV14-MZ0-65269705
rdf:type
n8:Vysledek skos:Concept
rdfs:seeAlso
http://dx.doi.org/10.1007/s00508-013-0395-2
dcterms:description
Authors analyze actual situation in treatment of cardiovascular diseases in older patients. Different groups of recommended drugs are discussed separately; possible risks for elderly patients are stressed. Angiotensin converting enzyme inhibitors-this group is widely used in older patients because of their hypotensive effect, positive influence on cardiac failure, and positive modulation of endothelial dysfunction. The risk of hyperkalemia must be considered. Antiaggregants and anticoagulants are proved as potent prophylactic treatment, but the associated risk of gastrointestinal bleeding must be weighed very carefully. Bradycardia related to beta-blockers, especially in combination with other medications lowering the heart rate must be taken into account. Otherwise, this group brings the highest profit in cardiovascular diseases as for morbidity and mortality. Attention is paid to calcium channel blockers, statins, diuretics, nitrates, and digoxin. A table listing the possible side effects and clinical symptoms of overdose by medications most frequently used in the elderly concludes the article.. Authors analyze actual situation in treatment of cardiovascular diseases in older patients. Different groups of recommended drugs are discussed separately; possible risks for elderly patients are stressed. Angiotensin converting enzyme inhibitors-this group is widely used in older patients because of their hypotensive effect, positive influence on cardiac failure, and positive modulation of endothelial dysfunction. The risk of hyperkalemia must be considered. Antiaggregants and anticoagulants are proved as potent prophylactic treatment, but the associated risk of gastrointestinal bleeding must be weighed very carefully. Bradycardia related to beta-blockers, especially in combination with other medications lowering the heart rate must be taken into account. Otherwise, this group brings the highest profit in cardiovascular diseases as for morbidity and mortality. Attention is paid to calcium channel blockers, statins, diuretics, nitrates, and digoxin. A table listing the possible side effects and clinical symptoms of overdose by medications most frequently used in the elderly concludes the article..
dcterms:title
Benefits and pitfalls of cardiovascular medication in seniors Benefits and pitfalls of cardiovascular medication in seniors
skos:prefLabel
Benefits and pitfalls of cardiovascular medication in seniors Benefits and pitfalls of cardiovascular medication in seniors
skos:notation
RIV/65269705:_____/13:#0002082!RIV14-MZ0-65269705
n8:predkladatel
n19:ico%3A65269705
n5:aktivita
n14:I n14:V
n5:aktivity
I, V
n5:cisloPeriodika
15-16
n5:dodaniDat
n11:2014
n5:domaciTvurceVysledku
n10:3160394 n10:4484630 n10:5584159 n10:9026592
n5:druhVysledku
n12:J
n5:duvernostUdaju
n17:S
n5:entitaPredkladatele
n16:predkladatel
n5:idSjednocenehoVysledku
63090
n5:idVysledku
RIV/65269705:_____/13:#0002082
n5:jazykVysledku
n13:eng
n5:klicovaSlova
Angiotensin converting enzyme inhibitors; Antiaggregants; beta-blockers; Statins; Calcium blockers; Diuretics; Digoxin; Pharmacotherapy in the elderly; Unwanted side effects; Medical interactions
n5:klicoveSlovo
n9:Antiaggregants n9:Diuretics n9:Unwanted%20side%20effects n9:Calcium%20blockers n9:Pharmacotherapy%20in%20the%20elderly n9:beta-blockers n9:Statins n9:Medical%20interactions n9:Angiotensin%20converting%20enzyme%20inhibitors n9:Digoxin
n5:kodStatuVydavatele
AT - Rakouská republika
n5:kontrolniKodProRIV
[01CA93F21CDB]
n5:nazevZdroje
Wiener klinische Wochenschrift
n5:obor
n15:FP
n5:pocetDomacichTvurcuVysledku
4
n5:pocetTvurcuVysledku
5
n5:rokUplatneniVysledku
n11:2013
n5:svazekPeriodika
125
n5:tvurceVysledku
Matějovská Kubešová, Hana Meluzínová, Hana Bielaková, Katarína Weber, Pavel
n5:wos
000323670700001
s:issn
0043-5325
s:numberOfPages
12
n18:doi
10.1007/s00508-013-0395-2